Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission
Background. Both exclusive enteral nutrition (EEN) and infliximab (IFX) are recommended as induction therapy for pediatric Crohn’s disease (CD). Our aim was to compare long-term disease outcomes of patients initially received with either IFX or EEN. Methods. Medical records of newly diagnosed, thera...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2022/3813915 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553008716578816 |
|---|---|
| author | Yao Lv Yue Lou Gan Yang Youyou Luo Jingan Lou Qi Cheng Jindan Yu Youhong Fang Hong Zhao Kerong Peng Jie Chen |
| author_facet | Yao Lv Yue Lou Gan Yang Youyou Luo Jingan Lou Qi Cheng Jindan Yu Youhong Fang Hong Zhao Kerong Peng Jie Chen |
| author_sort | Yao Lv |
| collection | DOAJ |
| description | Background. Both exclusive enteral nutrition (EEN) and infliximab (IFX) are recommended as induction therapy for pediatric Crohn’s disease (CD). Our aim was to compare long-term disease outcomes of patients initially received with either IFX or EEN. Methods. Medical records of newly diagnosed, therapy naïve pediatric patients with CD received with IFX or EEN as induction therapy were retrospectively enrolled. Pediatric Crohn’s disease activity index (PCDAI), Crohn’s disease endoscopic index of severity (CDEIS), and other clinical data were compared pre- and postinduction therapy in two groups. The sustained remission rates and time coupled with body mass index (BMI) and height for age (HFA) changes were evaluated during more than 2-year long-term follow-up. Results. We collected data from 58 children with CD used IFX (23) or EEN (35) as induction remission therapy from January 2015 through June 2021 in our single-center. The median follow-up after starting IFX or EEN was 12.2 months (6.5–18.0months) and 18.9 months (7.1–30.7months), respectively. The proportion clinical and endoscopic remission in EEN (88.57% and 68.75%) was similar with that of IFX (73.91% and 80.77%) after induction therapy. No significant differences were also observed in BMI and HFA recovery between two groups. Among those who achieved clinical or endoscopic remission or endoscopic response, the sustained remission rates and time did not reveal any significant differences for those 10 patients who used 6-mercaptopurine/methotrexate (6-MP/MTX) or 14 patients who used IFX as maintenance treatment during longitudinal follow-up. Conclusions. Our study suggested that EEN treatment is similar with IFX therapy in short-term outcomes, and EEN+6-MP/MTX treatment is comparable with IFX+IFX therapy in long-term outcomes. |
| format | Article |
| id | doaj-art-bed1f10af1ff4019a03f94eabaa4ccda |
| institution | Kabale University |
| issn | 1687-630X |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-bed1f10af1ff4019a03f94eabaa4ccda2025-02-03T05:57:22ZengWileyGastroenterology Research and Practice1687-630X2022-01-01202210.1155/2022/3813915Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction RemissionYao Lv0Yue Lou1Gan Yang2Youyou Luo3Jingan Lou4Qi Cheng5Jindan Yu6Youhong Fang7Hong Zhao8Kerong Peng9Jie Chen10Gastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentGastroenterology DepartmentBackground. Both exclusive enteral nutrition (EEN) and infliximab (IFX) are recommended as induction therapy for pediatric Crohn’s disease (CD). Our aim was to compare long-term disease outcomes of patients initially received with either IFX or EEN. Methods. Medical records of newly diagnosed, therapy naïve pediatric patients with CD received with IFX or EEN as induction therapy were retrospectively enrolled. Pediatric Crohn’s disease activity index (PCDAI), Crohn’s disease endoscopic index of severity (CDEIS), and other clinical data were compared pre- and postinduction therapy in two groups. The sustained remission rates and time coupled with body mass index (BMI) and height for age (HFA) changes were evaluated during more than 2-year long-term follow-up. Results. We collected data from 58 children with CD used IFX (23) or EEN (35) as induction remission therapy from January 2015 through June 2021 in our single-center. The median follow-up after starting IFX or EEN was 12.2 months (6.5–18.0months) and 18.9 months (7.1–30.7months), respectively. The proportion clinical and endoscopic remission in EEN (88.57% and 68.75%) was similar with that of IFX (73.91% and 80.77%) after induction therapy. No significant differences were also observed in BMI and HFA recovery between two groups. Among those who achieved clinical or endoscopic remission or endoscopic response, the sustained remission rates and time did not reveal any significant differences for those 10 patients who used 6-mercaptopurine/methotrexate (6-MP/MTX) or 14 patients who used IFX as maintenance treatment during longitudinal follow-up. Conclusions. Our study suggested that EEN treatment is similar with IFX therapy in short-term outcomes, and EEN+6-MP/MTX treatment is comparable with IFX+IFX therapy in long-term outcomes.http://dx.doi.org/10.1155/2022/3813915 |
| spellingShingle | Yao Lv Yue Lou Gan Yang Youyou Luo Jingan Lou Qi Cheng Jindan Yu Youhong Fang Hong Zhao Kerong Peng Jie Chen Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission Gastroenterology Research and Practice |
| title | Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission |
| title_full | Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission |
| title_fullStr | Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission |
| title_full_unstemmed | Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission |
| title_short | Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission |
| title_sort | outcomes of pediatric patients with crohn s disease received infliximab or exclusive enteral nutrition during induction remission |
| url | http://dx.doi.org/10.1155/2022/3813915 |
| work_keys_str_mv | AT yaolv outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT yuelou outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT ganyang outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT youyouluo outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT jinganlou outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT qicheng outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT jindanyu outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT youhongfang outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT hongzhao outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT kerongpeng outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission AT jiechen outcomesofpediatricpatientswithcrohnsdiseasereceivedinfliximaborexclusiveenteralnutritionduringinductionremission |